Cargando…

T cell epitope mapping of secukinumab and ixekizumab in healthy donors

Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab has also shown lower in vitro immunogenicity potential compared with other mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spindeldreher, Sebastian, Karle, Anette, Correia, Evelyne, Tenon, Maxime, Gottlieb, Sascha, Huber, Thomas, Maillere, Bernard, Kolbinger, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648323/ https://www.ncbi.nlm.nih.gov/pubmed/31924123 http://dx.doi.org/10.1080/19420862.2019.1707418

Ejemplares similares

Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
por: Spindeldreher, Sebastian, et al.
Publicado: (2018)

Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
por: Spindeldreher, Sebastian, et al.
Publicado: (2018)

Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
por: Karle, Anette, et al.
Publicado: (2016)

Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors
por: Hamze, Moustafa, et al.
Publicado: (2017)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2022)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?
por: Sordé, Laetitia, et al.
Publicado: (2017)

Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?
por: Sordé, Laetitia, et al.
Publicado: (2017)

Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells
por: de Bourayne, Marie, et al.
Publicado: (2022)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
por: Schweikert, Bernd, et al.
Publicado: (2020)

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
por: Berman, Julia, et al.
Publicado: (2021)

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Psoriasis patients utilizing secukinumab, ixekizumab, or brodalumab – comparisons to prior biologic medication adherence levels, reasons for switching, and reported changes in disease symptoms
por: Baiano, Renee, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
por: Schweikert, Bernd, et al.
Publicado: (2020)

Deciphering cross-species reactivity of LAMP-1 antibodies using deep mutational epitope mapping and AlphaFold
por: Pruvost, Tiphanie, et al.
Publicado: (2023)

Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro
por: Rombach-Riegraf, Verena, et al.
Publicado: (2014)

The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies
por: Wu, Chen-Yu, et al.
Publicado: (2019)

Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants
por: Gomez, Elisa V., et al.
Publicado: (2017)

A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors
por: Webster, Carl I., et al.
Publicado: (2016)

Ixekizumab-induced alopecia areata
por: Eldirany, Sherif A., et al.
Publicado: (2019)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
por: Li, Ying, et al.
Publicado: (2022)

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Large-scale mapping of the Ebola NP and GP proteins reveals multiple immunoprevalent and conserved CD4 T-cell epitopes
por: Gallais, Yann, et al.
Publicado: (2020)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

Pyoderma gangrenosum in a patient on ixekizumab
por: Pollack, Ilana R., et al.
Publicado: (2021)

Ixekizumab‐induced urticarial drug eruption
por: Kaneoka, Ayaka, et al.
Publicado: (2023)

Successful treatment of type II pityriasis rubra pilaris with secukinumab
por: Gauci, Marie-Léa, et al.
Publicado: (2016)

Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses
por: Azam, Aurélien, et al.
Publicado: (2021)

Human CD4 T cell epitopes selective for Vaccinia versus Variola virus
por: Probst, Alicia, et al.
Publicado: (2013)

Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab
por: Hanfstingl, Kathrin, et al.
Publicado: (2018)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
por: Lobo, Yolanka, et al.
Publicado: (2020)

Ixekizumab May Improve Renal Function in Psoriasis
por: Amoruso, Giuseppe Fabrizio, et al.
Publicado: (2021)

The role of ixekizumab in non-radiographic axial spondyloarthritis
por: San Koo, Bon, et al.
Publicado: (2021)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Behandlung der Psoriasis mit Secukinumab: Praxisrelevante Hinweise
por: Körber, Andreas, et al.
Publicado: (2021)

Specificity of the T Cell Response to Protein Biopharmaceuticals
por: Meunier, Sylvain, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hte0nskaq764q5at54si98ij9r